Egypt’s Rameda starts manufacturing Anvigan like drug for COVID-19 treatment
Rameda has also obtained approval from the Egyptian Drug Authority to manufacture Remedisivir
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has started manufacturing the antiviral Anviziram (which contains the same active ingredient as in Avigan) to treat coronavirus (COVID-19) patients.
The company will launch the drug within the Egyptian market with in three years, Amr Morsy, its managing director said.
“Anviziram contains the active pharmaceutical ingredient Favipiravir, which is the generic form of the antiviral sold under the brand name Avigan in Japan”
Rameda has also obtained approval from the Egyptian Drug Authority to manufacture Remedisivir for intravenous administration to treat COVID-19 patients.
The active pharmaceutical ingredient Favipiravir has been subjected to clinical trials for the treatment of COVID-19 in several countries such as China, Italy, Japan, and Russia.
The company will initially focus its Anviziram production on the Egyptian market and it is looking to export the medicine after obtaining approval from the Ministry of Health and the Egyptian Drug Authority.
It is worth mentioning that in the first quarter of 2020, Rameda logged net profits of 23.76 million Egyptian pounds, up from 8.33 million pounds in the year-ago period.
